Stockscreener 앱 받기
12.96
0.93%
0.12
시간 외 거래:
12.96
Atrium Therapeutics Inc 주식(RNA)의 최신 뉴스
Atrium Therapeutics, Inc. (RNA) Stock Analysis: 94.70% Potential Upside Catches Investor Attention - DirectorsTalk Interviews
Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership - Stock Titan
Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds - Stock Titan
T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A - Stock Titan
Atrium Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | RNA | US04965N1046 - marketscreener.com
Atrium Therapeutics Q2 Net Loss Widens to $21.6 Million on Higher Spending - Minichart
Atrium Therapeutics Earns $15M BMS Milestone Payment, Advances Gene Therapy Candidate - Minichart
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Heart drug developer Atrium Therapeutics' Q2 loss widens as expenses rise - TradingView
Atrium Therapeutics Q2 Results: Sales beat 50%, EPS miss widens - scanx.trade
Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary - TradingView
Atrium Therapeutics (RNA) grows collaboration revenue to $22.6M while scaling R&D spend - Stock Titan
Atrium Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
META_TITLE_QUOTE - Yahoo Finance
Atrium Therapeutics Reports Second Quarter 2026 Financial Results - KITV
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B - Fierce Biotech
Atrium Therapeutics Earns $15M BMS Milestone - Contract Pharma
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb By Investing.com - Investing.com Nigeria
Atrium Therapeutics Earns Another $15 Million Milestone Payment From Bristol Myers Squibb - marketscreener.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb - Investing.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a Potential 102.59% Upside in the Booming RNA Therapeutics Market - directorstalkinterviews.com
H.C. Wainwright Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Atrium Therapeutics (RNA) Climbs 1.99% to $11.77, Approaching Key Resistance at $12.36Volume Oscillator - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A 120% Upside Potential Awaits Investors - DirectorsTalk Interviews
BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing - Stock Titan
Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA - tradingview.com
Atrium Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockEarnings Forecast Report - dars.gov.et
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Atrium Therapeutics’ new hire receives options and 3,500 stock units - Stock Titan
Atrium Therapeutics (RNA): Flat Trading as Stock Hovers Near Key Support LevelsMonthly Profile - dars.gov.et
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA) - The Globe and Mail
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Commercial Spend Weighs on ResultsQuarterly Profit Report - dars.gov.et
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Provides a Modest SurpriseLow Estimate Range - dars.gov.et
Wells Fargo Maintains Atrium Therapeutics(RNA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Atrium’s ATR-1072 gains IND clearance for PRKAG2 syndrome - BioWorld News
Atrium Therapeutics Receives FDA Clearance for ATR 1072, Launches First Clinical Trial Targeting PRKAG2 Syndrome - Minichart
FDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drug - dicardiology.com
Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch - Stock Titan
Atrium Therapeutics Secures FDA Clearance for ATR 1072 Trial - grafa.com
Atrium gets FDA clearance for PRKAG2 syndrome trial - Investing.com UK
Atrium gets FDA clearance for PRKAG2 syndrome trial By Investing.com - Investing.com Nigeria
FDA clears Atrium Therapeutics' IND for ATR 107... - Pluang
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome - PR Newswire
FDA clears IND for Atrium Therapeutics' ATR 1072 trial - scanx.trade
Atrium Therapeutics (RNA) Slips 3.5% as Biotech Headwinds IntensifySuperTrend - dars.gov.et
Enterprise value to revenue forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to earnings forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Enterprise value to EBIT forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Price to sales forward of Atrium Therapeutics, Inc. – NASDAQ:RNA - TradingView
Atrium Therapeutics Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Atrium Therapeutics (RNA) Slips 3% as Shares Test Key Support at $12.31Delta Hedging - dars.gov.et
RNA News | ATRIUM THERAPEUTICS INC (NASDAQ:RNA) - ChartMill
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat on Narrower Loss, No Revenue Reported - dars.gov.et
Atrium Therapeutics, Inc.(NasdaqGS:RNA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Company Poised for Nearly 90% Upside - DirectorsTalk Interviews
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Growth Benchmark - marketscreener.com
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Clinical ProgressFiscal Year Earnings - dars.gov.et
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell Microcap Index - marketscreener.com
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to Russell 3000E Index - marketscreener.com
RNA Forecast — Price Target — Prediction for 2027 - TradingView
Atrium Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNA) - TradingView
RNA Technical Analysis & Stock Price Forecast - Intellectia AI
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline Progress ContinuesManagement Tone Analysis - po-news-eg.net
Arbiter Partners Capital Management LLC's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Cantor Fitzgerald Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Stage; Stock Inches HigherOperating Margin Analysis - Město Břeclav
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Unveiling a 111.86% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
1.80%
1.77%
자본화:
|
볼륨(24시간):